NewsLondon-Listed Medical Cannabis Firm Purchases Israeli Clinical Trial Specialist

London-Listed Medical Cannabis Firm Purchases Israeli Clinical Trial Specialist

-

LONDON Stock Exchange-listed MGC Pharmaceuticals is to acquire Israeli clinical trial specialist MediCaNL for £3.3m (A$6m) in a share-based transaction.

On completion of the acquisition, MediCaNL will design, manage and run all clinical trials for MGC Pharma in accordance with the European Medicines Agency, Federal Drug Administration and Israeli health regulations.

MGC Pharmaceuticals became the first cannabis company to be listed on the LSE in February this year and is now valid at over £80m. It will be undertaking multiple clinical trials in 2021/22 and in future years.

Its co-founder and managing director Roby Zomer said: “MediCaNL is led by some of the world’s most renowned doctors and scientists who will be a great asset to the MGC Pharma team. 

“By acquiring MediCaNL and bringing their services and expertise in-house, we not only cut significant costs from our forecasted clinical trial expenditure but also remove much of the red tape involved in the preclinical and clinical trial process.’

Roby Zomer

In 2020, MediCaNL generated revenues of almost $1m, with a profit margin of 25%. MGC will soon be undertaking one Phase III and two-Phase II clinical trials for CannEpil, CogniCann and CimertA, along with two Phase I clinical trials planned for the second half of 2021. 

MGC was initially listed on the Australian Securities Exchange before heading for a dual listing in London.

Peter
Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

UK First As Government Allocates £500,000 Funding For Innovate Cannabis Research 

THE UK Government through its innovation agency is set to provide almost £500,000 of funding to an English company...

British People Open To Using Medical Cannabis – Yet Majority Unaware They Can Access It On Prescription 

A NEW national survey of 4,000 people has highlighted the need to improve awareness of cannabis as a medicine.  Key...

As US Hemp Cultivation Levels Plummet The Established European Industry Continues To Flourish 

DESPITE a huge decline in US hemp industry’s footprint the European industry will continue to grow, say the continent’s...

Chrystal Capital Acts As Exclusive Advisor To Change Agronomy On £9.6m Fundraise

CHRYSTAL Capital Partners LLP, is an entrepreneurial corporate finance and investment house with an established global network of Single...

European Cannabis Stocks Review: ‘End’ Of US Cannabis Bear Market Rallies European Stocks 

FOLLOWING last week’s rally there has seen something of a lull with little movement for European cannabis stocks. Last week’s...

Business of Cannabis Conference Returns to New York City on November 3rd

In this second summit, the most influential business leaders, investors and politicians gather to discuss social equity, policy and...

Must read

UK First As Government Allocates £500,000 Funding For Innovate Cannabis Research 

THE UK Government through its innovation agency is set...

As US Hemp Cultivation Levels Plummet The Established European Industry Continues To Flourish 

DESPITE a huge decline in US hemp industry’s footprint...

You might also likeRELATED
Recommended to you